Advisory

2002-54
August 13, 2002
For immediate release

Health Canada is advising Canadians of incorrect information on new approved uses for Aspirin®

OTTAWA - Health Canada is advising Canadians of incorrect information released by Bayer Inc. about new approved uses for Aspirin®.

On July 31, 2002, Bayer Inc. issued a news release stating that "Health Canada has approved the use of ASPIRIN® (ASA) for primary prevention, to reduce the risk of first heart attacks and strokes in individuals deemed to be at sufficient risk."

This was not accurate. The new indication approved by Health Canada is ONLY for reducing the risk of first, non-fatal heart attacks, in individuals deemed at risk of such an event by their doctor. This indication applies only to the products Aspirin Tablets 325 milligrams and Coated Aspirin Daily Low Dose 81 milligrams and not to the whole Aspirin line of products. The products have not been approved for reducing the risk of fatal heart attacks or strokes.

Bayer Inc. issued a correction to the media on August 1, 2002, and will be providing corrected information to health care professionals. This advisory is to further support Health Canada's efforts to give the public accurate, up to date information.

-30-

Media Inquiries:
Ryan Baker
Health Canada
(613) 941-8189

Public Inquiries:
(613) 957-2991